These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29259959)

  • 21. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
    Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eriodicyol inhibits osteoclast differentiation and ovariectomy-induced bone loss in vivo.
    Lee J; Noh AL; Zheng T; Kang JH; Yim M
    Exp Cell Res; 2015 Dec; 339(2):380-8. PubMed ID: 26450448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melittin inhibits osteoclast formation through the downregulation of the RANKL-RANK signaling pathway and the inhibition of interleukin-1β in murine macrophages.
    Choe JY; Kim SK
    Int J Mol Med; 2017 Mar; 39(3):539-548. PubMed ID: 28204822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
    Sun X; Zhang J; Wang Z; Liu B; Zhu S; Zhu L; Peng B
    Theranostics; 2019; 9(18):5183-5199. PubMed ID: 31410209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression.
    Kwak HB; Kim HS; Lee MS; Kim KJ; Choi EY; Choi MK; Kim JJ; Cho HJ; Kim JW; Bae JM; Kim YK; Park BH; Ha H; Chun CH; Oh J
    Biol Pharm Bull; 2009 Jan; 32(1):45-50. PubMed ID: 19122279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation.
    Fuji H; Ohmae S; Noma N; Takeiri M; Yasutomi H; Izumi K; Ito M; Toyomoto M; Iwaki S; Takemoto K; Seo S; Taura K; Hida S; Aoyama M; Ishihama Y; Hagiwara M; Takeda N; Hatano E; Iwaisako K; Uemoto S; Asagiri M
    Biochem Biophys Res Commun; 2018 Sep; 503(2):544-549. PubMed ID: 29800570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
    Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
    Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetylpyridinium chloride inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast formation.
    Zheng T; Chen L; Noh AL; Yim M
    Biol Pharm Bull; 2013; 36(4):509-14. PubMed ID: 23546287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Miconazole inhibits receptor activator of nuclear factor-κB ligand-mediated osteoclast formation and function.
    Zheng T; Wang X; Yim M
    Eur J Pharmacol; 2014 Aug; 737():185-93. PubMed ID: 24842191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation.
    Wu L; Luo Z; Liu Y; Jia L; Jiang Y; Du J; Guo L; Bai Y; Liu Y
    Stem Cell Res Ther; 2019 Dec; 10(1):375. PubMed ID: 31805984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
    Rahman MM; Bhattacharya A; Fernandes G
    J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
    Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
    PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decursin from Angelica gigas suppresses RANKL-induced osteoclast formation and bone loss.
    Wang X; Zheng T; Kang JH; Li H; Cho H; Jeon R; Ryu JH; Yim M
    Eur J Pharmacol; 2016 Mar; 774():34-42. PubMed ID: 26825541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
    Hyeon S; Lee H; Yang Y; Jeong W
    Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
    Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Picroside II Inhibits RANKL-Mediated Osteoclastogenesis by Attenuating the NF-κB and MAPKs Signaling Pathway In Vitro and Prevents Bone Loss in Lipopolysaccharide Treatment Mice.
    Yang X; Gao W; Wang B; Wang X; Guo H; Xiao Y; Kong L; Hao D
    J Cell Biochem; 2017 Dec; 118(12):4479-4486. PubMed ID: 28464271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.